Experience of insulin degludec treatment using constant glucose monitoring system (CGMS)
- Authors: Smirnova E.Y.1
-
Affiliations:
- Endocrinology Center of the Kalininsky District City Outpatient Clinic № 86
- Issue: Vol 28, No 4 (2021)
- Pages: 110-115
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/313134
- DOI: https://doi.org/10.18565/pharmateca.2021.4.110-115
- ID: 313134
Cite item
Open Access
Access granted
Abstract
Patients with diabetes mellitus (DM) undergoing insulin therapy are nowadays not uncommon, but the routine practice of a doctor. Modern drugs provide a wide range of therapy options. The evolution of insulin in the 100 years since its discovery in 1921 and its successful use in 1922 has been incredibly fast. Despite this, it is impossible to speak of full compensation for absolutely all diabetic patients. So, in my practice, I encountered long-term decompensated patients who, for various reasons, were not able to achieve their goals in terms of glycemic control. A patient with decompensation confirmed after installation of continuous monitoring and subsequent correction of therapy was chosen as an example. With further follow-up, a clinically significant improvement in diabetes compensation was obtained, which I associate precisely with its transfer to insulin degludec. Stable compensation and the absence of progression of chronic complications of diabetes mellitus is the result we were striving for.
Full Text
About the authors
Ekaterina Yu. Smirnova
Endocrinology Center of the Kalininsky District City Outpatient Clinic № 86
Email: katrin_cat@list.ru
endocrinologist build. 3, 5 Kirishskaya St., St. Petersburg195299, Russian Federation
References
- IDF Diabetes Atlas, 8th edition. Brussels: international Diabetes Federation; 2017. Available from: https://www.idf.org/e-library/epidemiologyresearch/diabetesatlas/134-idf-diabetes-atlas-8th-edition.html
- Дедов И.И., Шестакова М.В., Викулова О.К. Эпидемиология сахарного диабета в Российской Федерации: клинико-статистический анализ по данным Федерального регистра сахарного диабета. Сахарный диабет. 2017;1(20):13-41.
- Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Под ред. И.И. Дедова, М.В. Шестаковой, А.Ю. Майорова. 9-й выпуск (дополненный). М., 2019. doi: 10.14341/DM221S1;10.
- McKnight J.A., et al. Glycaemic control of Type 1 diabetes in clinical practice early in the 21st century: an international comparison. Diabet Med 2015;32:1036-50. doi: 10.1111/dme.12676.
- Oguz A., Benroubi M., Brismar K., et al. Clinical outcomes after 24 months of insulin therapy in patients with type 2 diabetes in five countries: results from the TREAT study Curr Med Res Opin 2013;29:911-20. doi: 10.1185/03007995.2013.803053.
- Polinski J.M., Kim S.C., Jiang D., et al. Geographic patterns in patient demographics and insulin use in 18 countries, a global perspective from the multinational observational study assessing insulin use: understanding the challenges associated with progression of therapy (MOSAic). BMC Endocr Disord 2015;15:46. doi: 10.1186/s12902-015-0044-z.
- Mendivil C.O., Márquez-Rodrfguez E., Angel i.D, et al. Comparative effectiveness of vildagliptin in combination with other oral anti-diabetes agents in usual-care conditions: the EDGE-Latin America study. Curr Med Res Opin 2014;30:1769-76. doi: 10.1185/03007995.2014.928274.
- UK Prospective Diabetes Study (UKPDS) Group (1998) intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837-53. doi: 10.1016/S0140-6736(98)07019-6.
- Дедов И.И., Шестакова М.В., Аметов А.С. и др. Инициация и интенсификация сахароснижающей терапии больных сахарным диабетом 2 типа: обновление консенсуса совета экспертов Российской ассоциации эндокринологов (2015). Сахарный диабет. 2015;18(1):4-22.
- Осложнения сахарного диабета: лечение и профилактика. Под ред. И.И. Дедова, М.В. Шестаковой. М.: МИА, 2017. 744 с.
Supplementary files
